NEW YORK (GenomeWeb News) – Vermillion today announced the closing of a public offering of stock that raised $17.5 million in net proceeds.

The company offered 9,602,500 shares of common stock at $1.96 per share, including 1,252,500 shares sold pursuant to the underwriters' option to purchase additional shares.

Canaccord Genuity acted as sole book-running manager, and Roth Capital Partners was lead manager for the offering.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.